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Abstract
Background: Cytomegalovirus retinitis (CMVR) is one of the most common opportunistic infection in
immunocompromised individuals. Intravitreal ganciclovir injection has been used successfully but no
standard regimen was established. Risks of drug toxicity, endophthalmitis, and injection-related complications increased
with number and frequency of injection. The aim of this study is to evaluate the outcomes of reduced-dose intravitreal
ganciclovir (2 mg/0.04 mL) for the treatment of CMVR.
Methods: A prospective observational cohort study involving 67 eyes of 49 patients with CMVR was performed.
Induction therapy involved intravenous ganciclovir (10 mg/kg/day) for 2 weeks unless contraindicated or patients refused.
Patients were then treated with reduced-dose intravitreal ganciclovir every week for 4 weeks, and then every other week
until the lesion healed. The patients’ demographic data were recorded, and vision parameters were examined every visit.
Results: Twenty eyes (29.9 %) presented with initial visual acuities less than 6/60. The majority of patients were diagnosed
with CMVR in zones 1 or 2 (63 eyes, 94 %), and, at least, one quadrant of the retina was involved (56 eyes, 83.6 %).
Forty-one eyes (61.2 %) completely resolved after treatment within the 6-month follow-up. There was no significant
difference in healing time, whether or not patients received induction treatment with intravenous ganciclovir
(111.00 ± 12.96 vs 105.00 ± 28.32 days, p = 0.8). Five eyes (12.2 %) of patients with healed CMVR had visual acuities
less than 6/60.
Conclusions: Reduced-dose intravitreal ganciclovir is a safe and effective treatment option. It provides comparable
results to other weekly regimens. Induction with intravenous ganciclovir is not crucial in a resolution of retinitis,
although it may be necessary to reduce systemic cytomegalovirus loads and mortality rates.
Trial registration: The trial was registered with Thai Clinical Trials Registry (TCTR) on 16 March 2016 – TCTR20160316001.
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Background
Cytomegalovirus (CMV) is a DNA virus of the Herpesviridae
family. After primary infection, the virus becomes latent in
monocytes and endothelial cells for the remaining lifetime of
the patient. Reactivation of CMV infection may occur when
the host immune system is compromised. The most
common presentation is CMV retinitis (CMVR), espe-
cially in HIV/AIDS, lymphoma, and organ-transplanted
patients, and primary immunodeficiency diseases. The
most common manifestation of CMVR is the classic or
fulminant form, described as segmental necrotic retinitis
with intraretinal haemorrhage along the major vessels of
the retina [1]. The two other manifestations, granular and
perivascular forms, are less common. If left untreated, ret-
initis will progress, leading to blindness from the optic
nerve or foveal involvement, and retinal detachment.
Ganciclovir is recommended for treatment of CMVR [2].
It interferes with DNA polymerase, resulting in inhibition
of viral replication. The Food and Drug Administration of
the US has approved two routes of administration of ganci-
clovir for treatment of CMVR, an intravenous route and an
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intraocular implant. The intravenous ganciclovir (IVG)
showed a benefit of systemic CMV control and reduction
of mortality rate but the major complication is agranulo-
cytosis or pancytopenia. Intraocular implants demonstrated
local control of CMVR in the affected eye for 6 months
without systemic side effects [3, 4]. The need for retinal sur-
gery and the high risk of retinal detachment make this
method unfavourable. Both approved methods are expen-
sive and may not be appropriate for low- or middle-income
countries. Alternatively, intravitreal injection of ganciclovir
(IVTG) has been introduced [5–7]. This method is easy
and safe and provides fast and high intraocular drug con-
centrations. The reported dose varies from 0.2 to 5 mg of
ganciclovir [5–11]. To date, there was no standard regimen
in the treatment of CMVR with intravitreal ganciclovir
injection. The recommended injection interval is twice
weekly for 2 weeks, maintained with continuous weekly
injections until the patient’s immune system reaches a re-
constitution state and the lesion becomes a scar. The po-
tential complications from intraocular injection include
endophthalmitis, vitreous haemorrhage, and retinal vascular
occlusion; additionally, retinal detachment increases with
increased numbers and frequencies of injection [12].
Therefore, a less frequent injection should decrease the
risk of these complications and also lessened the burden on
compliance of patients and workload of healthcare per-
sonals, especially in low socioeconomic settings. In 2005,
Yutthitham and Ruamviboonsuk reported a successful re-
sult of high-dose (4 mg/0.1 ml), alternate-week intravitreal
injection of ganciclovir [11]. However, high dose (4 mg)
ganciclovir could result in toxicity, for example, we re-
ported a case of crystallization of 4-mg intravitreal ganciclo-
vir injection leading to retinal arterial occlusion and optic
atrophy [13]. With a consideration of toxicity from high
dose ganciclovir, we consequently reduced the regimen to
2-mg ganciclovir. From our observation, CMVR lesion
stopped in 2-4 weeks after induction with systemic ganci-
clovir. Therefore, in our regimen, the standard induction
with intravenous ganciclovir was introduced for 2 weeks if
the patient agreed to stay at the hospital and there was no
contraindication. After systemic induction, 4 weekly injec-
tions were given before reduction to alternated week injec-
tion. We considered this regimen to balance the efficacy,
side effects, and burden to patients and health workers in
low-middle income settings as our institute. We thus pro-
posed a reduced dose of four weekly 2-mg ganciclovir intra-
vitreal injections, followed by alternate week maintenance
for the treatment of CMVR, to reduce the frequency and
side effects of the intraocular injection.
Methods
This prospective observational cohort study was conducted
at the CMVR clinic of Siriraj Hospital, from November
2009 to September 2012. The study was approved by the
institutional review board of Siriraj Hospital, and adhered
to the tenets of the Declaration of Helsinki. Patients over
18 years of age with CMVR were recruited. Exclusion
criteria included previously treated CMVR or other con-
current retinal diseases. The diagnosis of cytomegalovirus
retinitis (CMVR) was made clinically by indirect ophthal-
moscopic findings. The CMVR findings included areas of
necrotic retinal infiltration with or without haemorrhage.
In addition, aqueous polymerase chain reaction (PCR) for
herpes CMV was performed to confirm the diagnosis in
some cases with controversial findings. After informed
consent was obtained, the patient was encouraged to re-
ceive induction treatment in the hospital with IVG at
5 mg/kg/dose every 12 h for 2 weeks, except for patients
who were contraindicated or were unable to remain at the
hospital. After the induction, patients were treated with
reduced-dose IVTG as directed. The reduced-dose IVTG
regimen included weekly injections of 2 mg/0.04 mL gan-
ciclovir for 4 weeks, followed by the same dosage every
other week until there was complete resolution of CMVR.
The IVTG was prepared at the date of injection
using the following protocol under sterile conditions.
Ganciclovir (Cymevene®; 500 mg; Roche, Basel, Switzerland)
was diluted with 10 mL of distilled water to give a 50-mg/
mL solution. Ganciclovir (2 mg/0.04 mL) was drawn and
kept in a 1-mL syringe. The injection was performed in the
treatment room. After being anaesthetized with topical
0.5 % tetracaine eye drops, the patient’s eye was cleaned with
10 % povidone-iodine and applied with 5 % povidone-iodine
eye drops before the operation. The intravitreal injection
was performed 4 mm from the limbus, using a 30-gauge
needle under sterile conditions. Topical 0.3 % ofloxacin eye
drops were given immediately after the injection, four times
daily for 3 days.
The patients’ demographic data were recorded, in-
cluding age, sex, laterality, underlying diseases, HIV
infection, CD4 count, and antiretroviral treatment.
Best corrected Snellen visual acuity (VA), intraocular
pressure (IOP) measurement, and a full eye examin-
ation using a slit-lamp biomicroscope and indirect
ophthalmoscope were performed initially and at every
follow-up visit. Full fundus photography was done ini-
tially and at 4-week intervals.
Statistical analysis was performed using descriptive
statistics for the proportion of eyes with the resolution
of CMVR within 6 months. A Kaplan–Meier graph
and Cox regression analysis were used to evaluate me-
dian time-to-resolution and factors affecting healing
times of CMVR. Subgroup analysis was compared be-
tween patients who received IVG with IVTG and with
IVTG alone. Chi-squared and paired t-tests were used
to compare the results between each group. All ana-
lyses were performed using SPSS software, version
18.0 (SPSS Inc., Chicago, IL, USA).
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Results
Sixty new CMVR cases were diagnosed from November
2009 to September 2012. Eleven patients were excluded
because of concomitant retinal detachment, because
they were already receiving standard IVG, or because of
an inability to follow the proposed IVTG regimen. Sixty-
seven eyes of 49 patients were analysed in the cohort.
Twenty-six patients (53.1 %) received complete treat-
ment with IVG followed by IVTG; the remaining
patients received only IVTG. Twelve patients withdrew
from the protocol (eight lost in follow-up, one because
of low platelets, one with no light perception, and two
died from sepsis). The patient demographic data are
summarized in Table 1. The mean age was 39.5 ±
9.4 years, with a slight male preponderance (57.1 %).
Thirty-one patients (63.3 %) presented with unilateral
CMVR. Most of the unilateral cases (61.3 %) received
IVTG without IVG. Forty-six patients (93.9 %) were
HIV positive with median CD4 counts of 21 cells/mm3
(range, 1–482). Five HIV positive patients (10.9 %) had
CD4 counts greater than 100 cells/mm3. Thirty-four pa-
tients (73.9 %) received antiretroviral treatment before
the diagnosis of CMVR. Of 37 patients treated in Siriraj
hospital, all patients received a fixed-dose combination
of lamivudine (3TC) 150 mg, stavudine (d4T) 30 mg,
and nevirapine (NVP) 200 mg before or concurrent with
CMVR treatment. The three non-HIV cases included
two patients with systemic lymphoma and one patient
who had received a kidney transplant. Eight cases under-
went aqueous aspiration for Herpes virus PCR. All of
them were CMV positive. One patient had co-infection
with VZV.
Forty-seven eyes (70.2 %) initially had a VA equal to or
better than 6/60, while 20 eyes (29.9 %) presented with
less than 6/60. The mean IOP before treatment was
11.15 ± 4.34 mmHg. Only one patient presented with
IOP of more than 20 mmHg and was successfully
treated with antiglaucoma eye drops. Most cases showed
zero to moderate anterior and vitreous inflammation.
There were 56 (83.58 %) and 62 (92.54 %) eyes with
grade 2+ cells or less in the anterior and vitreous cham-
bers, respectively.
Half of the patients were diagnosed with CMVR in
zone 1 (33 eyes, 49.3 %). Forty-one eyes (61.2 %) had ret-
initis extending equally to or less than one quadrant.
Forty-seven eyes (70.1 %) showed vasculitis before treat-
ment in at least one of the four major vessels. Papillitis
and foveal involvement were found in 14 eyes (20.9 %)
and 22 eyes (32.8 %), respectively.
Complete resolution of CMVR was observed in 41 eyes
(61.2 %) within a 6-month follow-up (Table 2). Excluding
patients lost to follow-up, the resolution percentage was
73.2 %. The mean number of injections was 8.5 ± 3.1 times.
The average time-to-resolution of CMVR was 97.2 ±
42.5 days (range, 21–188 days). In subgroup analysis, IVG
with IVTG required slightly longer time to resolve than
IVTG alone, although there was no statistically significant
difference in time-to-resolution between the two groups
(mean ± SD; 99.5 ± 45.3 vs 93.1 ± 38.3 days, respectively,
p = 0.65). No recurrence was seen during the follow-up
period. In cases of unilateral CMVR, there were no
patients with a second eye involvement during the
follow-up period. Thirty-four eyes (82.9 %) involving
successful resolution of CMVR had a VA that was
stable or improved after treatment. Thirty-six eyes
(87.8 %) had a VA equal to or better than 6/60. The
mean IOP was 11.6 ± 2.5 mmHg in eyes with complete
resolution. During treatment, there were no patients with
IOPs that exceeded 20 mmHg. In subgroup analyses, there
were no statistical differences between patients treated with
or without IVG, including the healing percentage, final VA,
and final IOP (Table 2). Thirteen of 67 eyes experienced
complications during treatment. Patients with CMVR reso-
lution had fewer side effects (5/41 eyes, 12.2 %; one patient
with transient acute visual loss, two patients with subcon-
junctival haemorrhages, and two patients with retinal de-
tachments) than patients who failed the regimen (8/26
eyes, 30.8 %; one patient with permanent visual loss, two
patients with severe pain, two patients with subconjunctival
haemorrhages, one patient with retinal detachment, and
two patients with vitreous haemorrhages).
Kaplan–Meier survival analysis showed that the regimen
reached a median resolution time at 111.00 ± 12.82 days
(95 % CI; 85.88–136.12). There was no significant differ-
ence in resolution time whether or not the patient received
IVG induction treatment (p = 0.8, log-rank test) (Fig. 1).
Multivariate Cox regression analysis indicated a shorter
resolution time in patients initially presenting with an age
younger than 45 years (HR 0.40; 95 % CI 0.17–0.93,
p = 0.03), with no vasculitis (HR 3.45; 95 % CI 1.52–
7.83, p = 0.003), or with no foveal involvement (HR
2.65; 95 % CI 1.14–6.11, p = 0.023) (Table 3). The
VA stabilization or improvement was affected by the
absence of vasculitis (HR 2.55; 95%CI 1.30–5.00, p =
0.007) and by the absence of retinitis in zone 1 (HR
0.51; 95 % CI 0.28–0.94, p = 0.03) (Table 4).
Discussion
Based on the present study, a reduced dose regimen
for IVTG, with a low percentage of complications, was
effective in controlling CMVR. Although systemic anti-
CMV therapy is the major treatment for CMVR, it is not
usually available in middle- and low-income countries such
as Thailand. IVG and oral valganciclovir are very expensive
for the general population, and these treatments have lim-
ited use because of systemic side effects. Alternative treat-
ments with various doses of IVTG have been successful in
many countries [5–11, 14–16], but the suggested protocols
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still need frequent follow-up visits. It is difficult for patients
with low socioeconomic status to follow these protocols,
because of other burdens, especially transportation costs.
Our reduced-dose protocol attempted to decrease
expenses, patient visits, and medical personnel work-
loads while producing reasonable results. It demon-
strated 73.2 % complete resolution of CMVR, without
recurrence, within 6 months of treatment. The average
healing time was about 14 weeks (3–27 weeks) with an
average of 8.3 injections. Resolution of the lesion
needed longer times than weekly maintenance proto-
cols. This agrees with other reports of alternate week
regimens [11, 15]. This is probably due to insufficient
drug concentration in the vitreous that is below the
50 % minimal inhibitory concentration (MIC50) during
the second week, although other factors may help ces-
sation of CMVR, such as antiretroviral treatment and
improvement of the patient’s immune status. Increas-
ing the dosage of ganciclovir may elevate the vitreous
concentration and shorten the healing time, but may
also result in optic nerve or macular toxicity [13, 17].
Using subgroup analyses, there was no statistical sig-
nificance in healing times and healing percentages be-
tween eyes with or without IVG induction.
Table 1 Baseline characteristics of patients with cytomegalovirus retinitis
IVTG alone IVG + IVTG Total
Patient-specific characteristics N = 23 N = 26 N = 49
Age in years (mean ± SD) 40.52 ± 11.62 38.62 ± 7.01 39.51 ± 9.40
Male (%) 12 (52.17) 16 (61.54) 28 (57.14)
Bilateral involvement (%) 4 (17.39) 14 (53.85) 18 (36.73)
HIV infection (%) 20 (86.96) 26 (100) 46 (93.88)
Concurrent anti-retroviral therapy (%) 13 (56.52) 21 (80.77) 34 (69.39)
Mean initial CD4 (cells/mm3)(range) 49.50 (1–482) 45.60 (2–200) 47.23 (1–482)
Eye-specific characteristics N = 27 N = 40 N = 67
Initial visual acuity (%)
-6/60 or better 19 (70.37) 28 (70.00) 47 (70.15)
-worse than 6/60 to HM 6 (22.22) 10 (25.00) 16 (23.88)
-worse than HM 2 (7.41) 2 (5.00) 4 (5.97)
Initial IOP in mmHg (mean ± SD) 12.00 ± 5.90 10.58 ± 2.81 11.15 ± 4.34
Initial anterior chamber cella (%)
-2+ or less 23 (85.19) 33 (82.50) 56 (83.58)
-more than 2+ 4 (14.81) 7 (17.50) 11 (16.42)
Initial vitreous cella (%)
-2+ or less 25 (92.59) 37 (92.50) 62 (92.54)
-more than 2+ 2 (7.41) 3 (7.50) 5 (7.46)
Worst location involvedb (%)
-Zone 1 12 (44.45) 21 (52.50) 33 (49.25)
-Zone 2 14 (51.85) 16 (40.00) 30 (44.78)
-Zone 3 1 (3.70) 3 (7.50) 4 (5.97)
Location size (%)
-less than 25 % 6 (22.22) 5 (12.50) 11 (16.42)
-25–49 % 18 (66.67) 31 (72.50) 49 (73.13)
-50 % and more 3 (11.11) 4 (10.00) 7 (10.45)
Frosted branch angiitis presented (%) 17 (62.96) 30 (75.00) 47 (70.15)
Papillitis presented (%) 8 (29.63) 6 (15.00) 14 (20.89)
Foveal involvement (%) 9 (33.33) 13 (32.50) 22 (32.84)
IVTG intravitreal ganciclovir, IVG intravenous ganciclovir, IOP intraocular pressure, HM hand motion, SD standard deviation
aAnterior and vitreous reaction according to the Standardization of Uveitis Nomenclature guideline
bWorst zone of retina involved; Zone 1, lesions located in the area of the retina within 1500 microns from the edge of the optic nerve or within 3000 microns
from the centre of the fovea. Zone 2, lesion located from the edge of zone 1 anteriorly to the circle of the vortex vein. Zone 3, lesion located anteriorly from zone
2 to the ora serrata
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At the conclusion of treatment, VA was stable or im-
proved in 73 % of all eyes. In patients with complete reso-
lution, VA improved or stabilized in 83 % of eyes. Eyes
treated with IVTG alone resulted in even better vision
preservation than those with IVG induction. This is prob-
ably because of the smaller area of retinitis. Our protocol
showed better results in preserving vision than previous
reports of IVG treatment [11, 15, 16, 18]. A previous re-
port, involving alternate week injections of 4 mg/0.1 mL,
showed a better resolution percentage of 82.4 % within
about 12 weeks (2–36 weeks) but only 51 % of patients
had vision preserved [11]. It demonstrated that a higher
dose of ganciclovir injection may increase the percentages
of resolution, but also increases the risk of ganciclovir tox-
icity, with a decreased final vision.
Young et al. reported a 100 % success percentage with
three biweekly 2 mg/0.1 mL of IVTG followed by weekly
IVTG maintenance. However, it resulted in a 7 % relapse
with median relapse time of 42 weeks [19]. In our co-
hort, there was no relapse after stopping the medication,
but the follow-up time was limited to 24 weeks, which
was probably insufficient to evaluate the actual relapse
time of IVTG. Nonetheless, it was much longer than the
8-week relapsing period of the IVG. Owing to cost limi-
tations, we did not evaluate the CD4 counts at the time
of CMVR resolution, but a cessation of injections with-
out recurrence or progression of lesions may signify the
recovery of the patient’s immune system.
The complication percentage from our cohort was 16.4 %
compared with 8.3 to 20.6 % using other IVTG regimens
[11, 15, 16, 19]. Most complications were minor, including
subconjunctival haemorrhage, pain, and transient visual
loss, except for three eyes with rhegmatogenous retinal de-
tachment and one eye with an acute permanent visual loss.
There was no endophthalmitis in our study while it was
Fig. 1 Kaplan–Meier graph showing complete resolution of cytomegalovirus (CMVR) lesions in eyes that received reduced-dose intravitreal ganciclovir
injection alone, compared with eyes that received reduced-dose intravitreal combined with intravenous ganciclovir injection
Table 2 Results of reduced-dose intravitreal ganciclovir
treatment for CMVR
IVTG alone IVG + IVTG Total
Healed CMVR (%) 15/27 (55.56) 26/40 (65.00) 41/67 (61.19)
Visual acuity in healed CMVR (%)
-6/60 or better 14 (93.33) 22 (84.62) 36 (87.81)
-worse than 6/60 to HM 1 (6.67) 3 (11.54) 4 (9.75)
-worse than HM 0 (0.00) 1 (3.84) 1 (2.44)
IOP in mmHg (mean ± SD) 12.20 ± 1.69 11.23 ± 2.86 11.59 ± 2.52
Complications (%) 2 (13.3) 3 (11.5) 5 (12.2)
IVTG intravitreal ganciclovir, IVG intravenous ganciclovir, CMVR
cytomegalovirus retinitis, HM hand motion, IOP intraocular pressure, SD
standard deviation
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reported in other IVTG studies with comparable patient
numbers [11, 16]. The absence of endophthalmitis in our
study may result from improvements in injection tech-
niques and use of antibiotics.
In our study, the median time-to-resolution of CMVR
was about 16 weeks. There was no significant difference
whether or not patients received IVG prior to IVTG.
Therefore, our findings indicated that IVG induction
was not needed for the resolution of CMVR. However,
because IVG helps in eradication of the systemic CMV
viral load, prevents the risk of extraocular or second eye
involvement, and reduces the mortality rate of patients,
we still encourage induction with IVG if available or not
contraindicated [20].
Based upon regression analyses, patients younger than
45 years old, without vasculitis, and without foveal lesions
were associated with shorter time-to-resolution of CMVR.
Gender, VA, induction with IVG, CD4 counts, and extent
or zone of retinitis at presentation showed no associations
with healing times. Younger patients may possess a better
immune function, despite their CD4 counts, and may,
therefore, respond faster to treatment. Vascular and foveal
involvement may indicate more complicated cases, requir-
ing longer healing periods. Patients with retinitis not in-
volving zone 1 and with an absence of vasculitis were
associated with improvement or preservation of the final
VA. These results indicate that the central retina and vas-
cular structure play crucial roles in visual prognosis.
Table 3 Univariate and multivariate Cox regression analyses of factors involving healing time
Factors Univariate Multivariate
p HR (95 % CI) p HR (95 % CI)
Age younger than 45 years old 0.013 2.86 (1.25–6.67) 0.033 2.5 (1.08–5.88)
Male 0.247 1.46 (0.77–2.67) 0.382 1.51 (0.60–3.83)
Induction with intravenous ganciclovir 0.798 1.09 (0.57–2.07) 0.494 1.26 (0.65–2.44)
Initial CD4 > 100 0.287 1.58 (0.68–3.67)
Concurrent anti-retroviral therapy 0.324 1.43 (0.70–2.92)
Initial visual acuity of 6/60 or better 0.335 1.42 (0.69–2.92)
No zone 1 involvement 0.717 1.12 (0.60–2.08) 0.091 0.50 (0.23–1.12)
Area of retinitis less than 25 % 0.258 1.45 (0.76–2.78) 0.500 1.41 (0.52–3.83)
No foveal involvement 0.162 1.64 (0.82–3.29) 0.023 2.65 (1.14–6.11)
No disc involvement 0.345 1.43 (0.68–3.01)
Frosted branch angiitis not presented 0.007 2.58 (1.29–5.16) 0.003 3.45 (1.52–7.83)
HR hazard ratio, CI confidence interval
aZone 1, lesions located in the area of the retina within 1500 microns from the edge of the optic nerve or within 3000 microns from the centre of the fovea
Table 4 Univariate and multivariate Cox regression analyses of factors involving vision stabilization or improvement
Factors Univariate Multivariate
p HR (95 % CI) p HR (95 % CI)
Age younger than 45 years old 0.054 2.04 (0.99–4.17) 0.062 1.96 (0.96–4.00)
Male 0.044 1.87 (1.02–3.42) 0.197 1.54 (0.80–2.95)
Induction with intravenous ganciclovir 0.372 0.77 (0.44–1.36) 0.533 0.83 (0.46–1.49)
Initial CD4 > 100 0.467 0.68 (0.24–1.92)
Concurrent anti-retroviral therapy 0.958 1.02 (0.55–1.88)
Initial visual acuity of 6/60 or better 0.312 0.74 (0.41–1.33)
No zone 1 involvementa 0.122 0.64 (0.36–1.13) 0.030 1.96 (1.07–3.58)
Area of retinitis less than 25 % 0.252 0.71 (0.39–1.28) 0.192 0.59 (0.27–1.30)
No foveal involvement 0.885 0.96 (0.53–1.72)
No disc involvement 0.670 1.15 (0.60–2.22)
Frosted branch angiitis not presented 0.017 2.18 (1.15–4.13) 0.007 2.55(1.30–5.00)
HR hazard ratio, CI confidence interval
aZone 1, lesions located in the area of the retina within 1500 microns from the edge of the optic nerve or within 3000 microns from the centre of the fovea
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There were limitations in our study, including it being
a nonrandomized trial with a small sample size. How-
ever, we selectively excluded CMVR patients with other
retinal diseases to minimize the bias of the treatment re-
sults. Our study is the first prospective cohort study
from Thailand; we thus believe our results could be rele-
vant to real ophthalmic clinical settings specifically for
low- to middle-income countries. A larger randomised
control trial should be conducted in the future to pro-
vide a better understanding of the different regimens.
Conclusions
In conclusion, our reduced-dose regimen of IVTG for
CMVR represents an efficacious and safe alternative ther-
apy, especially for resource-scarce settings. The resolution
of CMVR was achieved in favourable numbers of patients
within 6 months, When compared with other regimens,
the final visual outcome was better, while the complication
rates were similar. IVG induction may be required to
eradicate systemic CMV viral loads, but is not necessary
for treatment of ocular CMVR. With an average of eight
injections per person, both workloads and patient visits
are reduced. We, therefore, recommend this reduced-dose
regimen for treatment of CMVR, particularly in low- or
middle-socioeconomic settings.
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